Pliant Therapeutics (PLRX) Change in Accured Expenses (2019 - 2026)

Pliant Therapeutics (PLRX) has reported Change in Accured Expenses for 8 consecutive years, with -$6.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Accured Expenses fell 34.65% year-over-year to -$6.5 million; the TTM figure through Mar 2026 stood at -$13.8 million (down 15101.1% YoY), while the FY2025 annual figure was -$12.2 million, down 419.6% from the prior year.
• Change in Accured Expenses eased to -$6.5 million in Q1 2026 per PLRX's latest filing, from -$1.5 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $5.8 million in Q2 2022 and bottomed at -$6.5 million in Q1 2026.
• Historically, Change in Accured Expenses has averaged -$244058.8 across 5 years, with a median of -$538000.0 in 2023.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses soared 659.95% — and 2024, when it plunged 976.68%.
• Pliant Therapeutics' Change in Accured Expenses stood at -$411000.0 in 2022, then jumped by 270.07% to $699000.0 in 2023, then slumped by 976.68% to -$6.1 million in 2024, then soared by 75.29% to -$1.5 million in 2025, then sank by 327.61% to -$6.5 million in 2026.
• Business Quant data shows PLRX's Change in Accured Expenses at -$6.5 million in Q1 2026, -$1.5 million in Q4 2025, and -$2.0 million in Q3 2025.